Mares Virginia, Nehemy Marcio B, Bogunovic Hrvoje, Frank Sophie, Reiter Gregor S, Schmidt-Erfurth Ursula
Laboratory for Ophthalmic Image Analysis, Department of Ophthalmology and Optometry, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Int J Retina Vitreous. 2024 Apr 8;10(1):31. doi: 10.1186/s40942-024-00549-1.
Artificial intelligence (AI) has emerged as a transformative technology across various fields, and its applications in the medical domain, particularly in ophthalmology, has gained significant attention. The vast amount of high-resolution image data, such as optical coherence tomography (OCT) images, has been a driving force behind AI growth in this field. Age-related macular degeneration (AMD) is one of the leading causes for blindness in the world, affecting approximately 196 million people worldwide in 2020. Multimodal imaging has been for a long time the gold standard for diagnosing patients with AMD, however, currently treatment and follow-up in routine disease management are mainly driven by OCT imaging. AI-based algorithms have by their precision, reproducibility and speed, the potential to reliably quantify biomarkers, predict disease progression and assist treatment decisions in clinical routine as well as academic studies. This review paper aims to provide a summary of the current state of AI in AMD, focusing on its applications, challenges, and prospects.
人工智能(AI)已成为跨领域的变革性技术,其在医学领域,尤其是眼科的应用受到了广泛关注。大量高分辨率图像数据,如光学相干断层扫描(OCT)图像,推动了该领域人工智能的发展。年龄相关性黄斑变性(AMD)是全球失明的主要原因之一,2020年全球约有1.96亿人受其影响。长期以来,多模态成像一直是诊断AMD患者的金标准,然而,目前常规疾病管理中的治疗和随访主要由OCT成像驱动。基于人工智能的算法凭借其精确性、可重复性和速度,有潜力在临床常规以及学术研究中可靠地量化生物标志物、预测疾病进展并协助治疗决策。本文旨在总结人工智能在AMD领域的现状,重点关注其应用、挑战和前景。